Dr. Harold E. Selick has been the Chairman of the company and Director since 2009. Prior to this, he served as the Chief Executive Officer Threshold Pharmaceuticals, which recently merged with Molecular Templates. Dr. Selick also served as the Chief Executive Officer of Camitro Corporation; Vice President of Research at Affymax Research Institute. Currently, he also serves as the Vice Chancellor for Business Development, Innovation and Partnerships at University of California San Francisco and Chairman of Molecular Templates.

Mr. Dinesh V. Patel has been the Chief Executive Officer, President and Director of the company since 2008. Prior to this, he served as the President and Chief Executive Officer of Arete Therapeutics from 2006 to 2008; President and Chief Executive Officer of Miikana Therapeutics. Mr. Patel also served as the Senior Vice President of Drug Discovery and Licensing at Vicuron and Director of Chemistry at the Affymax. Earlier, he also served as the Medicinal Chemist at Bristol Myers Squibb from 1985 to 1993.

Mr. Asif Ali has been the Executive Vice President and Chief Financial Officer of the company since April 2022. Prior to this, he served as the Chief Accounting Officer and Vice President in Finance division at Theravance Biopharma from 2018 to 2022; Vice President and Controller at Depomed, Inc from 2012 to 2018. Mr. Ali also served as the Director of Finance and Accounting for Nevada Property from 2010 to 2011; Public Accounting in the life sciences practice of PricewaterhouseCoopers from 2004 to 2009.

Mr. Mohammad Masjedizadeh has been the Chief Technical Officer and Executive Vice President of the company since 2021. Prior to this, he served as the Executive Vice President of Pharmaceutical Development from 2017 to 2021; Vice President and Senior Director of Technical Operations at Principia Biopharma from 2012 to 2017. Mr. Masjedizadeh also worked at Roche Pharmaceuticals as a Director of Drug Substance & Supply from 1991 to 2012.

Mr. Arturo Molina has Chief Medical Officer of the company since November 2022. Prior to this, he served as a Chief Medical Officer at Sutro Biopharma from 2017 to 2022; Vice President of Oncology Scientific Innovation at Johnson & Johnson; Chief Medical Officer at Cougar Biotechnology. Mr. Molina also served as the Staff Physician in the Department of Hematology/Bone Marrow Transplantation and Department of Medical Oncology/Therapeutics Research at City of Hope Comprehensive Cancer Center from 1991 to 2002.